Compare · NNNN vs ORKA
NNNN vs ORKA
Side-by-side comparison of Anbio Biotechnology (NNNN) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NNNN and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NNNN is the larger of the two at $4.00B, about 1.1x ORKA ($3.67B).
- Over the past year, NNNN is up 332.1% and ORKA is up 611.4% - ORKA leads by 279.3 points.
- ORKA has been more active in the news (12 items in the past 4 weeks vs 8 for NNNN).
- ORKA has more recent analyst coverage (11 ratings vs 0 for NNNN).
PerformanceNNNN+332.10%ORKA+611.43%
2025-04-29+0.00%2026-04-28
- Company
- Anbio Biotechnology
- Oruka Therapeutics Inc.
- Price
- $28.00+1.86%
- $74.06-3.05%
- Market cap
- $4.00B
- $3.67B
- 1M return
- +17.65%
- +66.48%
- 1Y return
- +332.10%
- +611.43%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 8
- 12
- Recent ratings
- 0
- 11
Latest NNNN
- SEC Form 6-K filed by Anbio Biotechnology
- Amendment: SEC Form 20-F/A filed by Anbio Biotechnology
- SEC Form 3 filed by new insider Song Suki
- SEC Form 3 filed by new insider Hartzler Nancy
- SEC Form 3 filed by new insider Lau Michael
- SEC Form 3 filed by new insider Tian Chris
- SEC Form 3 filed by new insider Xu Cany
- SEC Form 20-F filed by Anbio Biotechnology
- Anbio Biotechnology to Participate in KeyBanc Capital Markets Healthcare Forum
- SEC Form 6-K filed by Anbio Biotechnology
Latest ORKA
- Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering
- SEC Form 424B5 filed by Oruka Therapeutics Inc.
- SEC Form 424B5 filed by Oruka Therapeutics Inc.
- Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering
- Oruka Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis
- Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026
- SEC Form 424B7 filed by Oruka Therapeutics Inc.
- SEC Form DEFA14A filed by Oruka Therapeutics Inc.
- SEC Form DEF 14A filed by Oruka Therapeutics Inc.